Femoropopliteal Artery Stent Thrombosis

Original Title: Femoropopliteal Artery Stent Thrombosis. Report from the Excellence in Peripheral Artery Disease Registry. Reference: Subhash Banerjee et al. Circ Cardiovasc Interv. 2016 Feb;9(2):e002730.

 

There is limited information on peripheral stent thrombosis and involved factors.

This study analyzed 604 stent procedures in femoropopliteal territory form the multicenter registry “Excellence in Peripheral Artery Disease”.

Stent thrombosis occurred in 26 of the 604 patients (4.3%) at median 6 month follow up post procedure.

Stent thrombosis was more frequent in men and when the lesion originally treated was a chronic total occlusion.

There were no differences in stent thrombosis between drug-coated and bare metal stents (4.4% vs 3.4%; p=0.55) but there were differences between self-expandable covered stents vs. conventional bare metal stents (10.6% vs 3.4%; p=0.02).

Thrombosis was associated to a much higher risk of adverse events over the same treated limb (HR, 4.99; CI 95% 2.31 to 10.77; p<0.001).

Multivariable analysis showed that chronic total occlusion (OR, 3.46; IC 95% 0.98 a 12.20; p=0.05) and in-stent restenosis (OR, 5.30; IC 95%, 1.83 a 15.32; p=0.002) were independently associated with stent thrombosis.

Conclusion
This multicenter registry of peripheral intervention showed that femoropopliteal stent thrombosis is 4.3% and is associated to the treatment of chronic total occlusions and restenosis of previous stents. Thrombosis is strongly associated to adverse events in this lower limb.

More articles by this author

SPYRAL Program: 3-Year Outcomes in Patients Treated with Renal Denervation

Hypertension is the leading modifiable risk factor for cardiovascular disease and remains a major global health challenge, affecting more than one billion adults worldwide.  Despite...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

SCAI 2026 | Deep vein arterialization as an alternative in patients with critical limb ischemia without conventional options

Critical limb ischemia (CLI) represents one of the most advanced stages of peripheral arterial disease (PAD). In a significant proportion of patients, distal anatomy,...

C-TRACT: Endovascular therapy in post-thrombotic syndrome due to iliac obstruction

Post-thrombotic syndrome (PTS) is one of the most limiting sequelae following proximal deep vein thrombosis (DVT). It clinically manifests as chronic pain, edema, skin...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

SPYRAL Program: 3-Year Outcomes in Patients Treated with Renal Denervation

Hypertension is the leading modifiable risk factor for cardiovascular disease and remains a major global health challenge, affecting more than one billion adults worldwide.  Despite...

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...